RxDoctor Payments Data

Joseph Sabat, MD

Vascular Surgery · Tucson, AZNPI 1538426069

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (57.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Angiodynamics, Inc. at 57.9% of the total. 2025 is the largest year on record at $16,668, 4.6 times the $3,589 reported in 2019.

$47,658in general payments, 2019–2025

Across 290 payments — averaging $164.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$28K
  • Inari Medical, Inc.$6K
  • Silk Road Medical, Inc.$2K
  • Boston Scientific$2K
  • Medtronic$1K
  • Abbott$1K
  • plus $7K from 35 others
$92,051in research payments, 2019–2025

Across 28 payments — averaging $3287.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bolton Medical Inc$38K
  • Medtronic$26K
  • Abbott$18K
  • Boston Scientific$10K

What the payments were for

  • Consulting fees$5,02511%
  • Grants$1,3033%
  • Travel & lodging$1,5383%
  • Food & beverage$12,16926%
  • Education$1220%
  • Other$27,50058%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,658 in reported general payments places this provider in the 85th percentile of 105 vascular surgery providers in Arizona.

See all vascular surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$418,561
Medicare patients
493
Services billed
1,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$80,679
XareltoRivaroxaban45$50,378
SantylCollagenase Clostridium Hist.15$5,022
Cilostazol96$2,569
ClopidogrelClopidogrel Bisulfate181$1,899
Atorvastatin Calcium81$590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$131$80,67981 claims
Johnson & JohnsonXarelto$200$50,37845 claims
Smith+NephewSantyl$233$5,02215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 vascular surgery providers in Arizona.

Other vascular surgery in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →